PMID- 21615671
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 13
IP  - 10
DP  - 2011 Oct
TI  - Metabolic effects of muraglitazar in type 2 diabetic subjects.
PG  - 893-902
LID - 10.1111/j.1463-1326.2011.01429.x [doi]
AB  - AIM: To assess the effect of muraglitazar, a dual peroxisome 
      proliferator-activated receptor (PPAR)gamma-alpha agonist, versus placebo on metabolic 
      parameters and body composition in subjects with type 2 diabetes mellitus (T2DM). 
      METHODS: Twenty-seven T2DM subjects received oral glucose tolerance test (OGTT), 
      euglycaemic insulin clamp with deuterated glucose, measurement of total body fat 
      (DEXA), quantitation of muscle/liver (MRS) and abdominal subcutaneous and 
      visceral (MRI) fat, and then were randomized to receive, in addition to diet, 
      muraglitazar (MURA), 5 mg/day, or placebo (PLAC) for 4 months. RESULTS: HbA1c(c) 
      decreased similarly (2.1%) during both MURA and PLAC treatments despite 
      significant weight gain with MURA (+2.5 kg) and weight loss with PLAC (-0.7 kg). 
      Plasma triglyceride, LDL cholesterol, free fatty acid (FFA), hsCRP levels all 
      decreased with MURA while plasma adiponectin and HDL cholesterol increased (p < 
      0.05-0.001). Total body (muscle), hepatic and adipose tissue sensitivity to 
      insulin and beta cell function all improved with MURA (p < 0.05-0.01). 
      Intramyocellular, hepatic and abdominal visceral fat content decreased, while 
      total body and subcutaneous abdominal fat increased with MURA (p < 0.05-0.01). 
      CONCLUSIONS: Muraglitazar (i) improves glycaemic control by enhancing insulin 
      sensitivity and beta cell function in T2DM subjects, (ii) improves multiple 
      cardiovascular risk factors, (iii) reduces muscle, visceral and hepatic fat 
      content in T2DM subjects. Despite similar reduction in A1c with PLAC/diet, 
      insulin sensitivity and beta cell function did not improve significantly.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Fernandez, M
AU  - Fernandez M
AD  - University of Texas Health Science Center and Texas Diabetes Institute, San 
      Antonio, TX 78229-3900, USA.
FAU - Gastaldelli, A
AU  - Gastaldelli A
FAU - Triplitt, C
AU  - Triplitt C
FAU - Hardies, J
AU  - Hardies J
FAU - Casolaro, A
AU  - Casolaro A
FAU - Petz, R
AU  - Petz R
FAU - Tantiwong, P
AU  - Tantiwong P
FAU - Musi, N
AU  - Musi N
FAU - Cersosimo, E
AU  - Cersosimo E
FAU - Ferrannini, E
AU  - Ferrannini E
FAU - DeFronzo, R A
AU  - DeFronzo RA
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Oxazoles)
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
RN  - TE7660XO1C (Glycine)
RN  - W1MKM70WQI (muraglitazar)
SB  - IM
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Female
MH  - Glucose Clamp Technique
MH  - Glucose Tolerance Test
MH  - Glycated Hemoglobin/*drug effects/metabolism
MH  - Glycine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology
MH  - Insulin Resistance
MH  - Insulin-Secreting Cells/*drug effects/metabolism
MH  - Intra-Abdominal Fat/*drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Oxazoles/administration & dosage/*pharmacology
MH  - Peroxisome Proliferator-Activated Receptors/*agonists/metabolism
EDAT- 2011/05/28 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/05/28 06:00
PHST- 2011/05/28 06:00 [entrez]
PHST- 2011/05/28 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1111/j.1463-1326.2011.01429.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2011 Oct;13(10):893-902. doi: 
      10.1111/j.1463-1326.2011.01429.x.